Read More Pharma Industry News Can Ampligen improve immunotherapy durability in recurrent ovarian cancer treatment? Can AIM ImmunoTech Inc.’s Ampligen improve immunotherapy durability in ovarian cancer? Explore the Phase 2 data and industry impact. bySoujanya RaviMay 9, 2026